Lecture 10 - Managing and Preventing Metabolic Syndrome Flashcards
Describe the weight loss trial for MS
Individuals:
• BMI 30-35
• 38% Metabolic syndrome in both groups
Two groups: 1. Medical therapy • VLCD • Optifast • Orlistat (inhibits lipase) • Behavioural therapy
- Surgical intervention
• LAP-BAND placement
Results:
• 0-6 mths: both groups showed same rates of weight loss
• >6 mths: medical group had weigh regain; surgical group had continued and sustained weight loss
Effects on MS:
• Medical group: 24% of individuals had MS at end
• Surgical group: 3% of individuals had MS at end
Conclusions:
• Surgical intervention with placement of LAP-BAND leads to superior weight loss and resolution of metabolic syndrome in comparison to medical therapy
Can genetics account for the epidemic of obesity?
No
Rates of obesity have increased from 7% to 18.4% in the last 30 years
Genetic drift does not occur at a rate to account for this
Describe Levin’s study in mice of epigenetics in obesity
Two groups of mice:
1. CHOW diet
• ‘Control’
• Normal weight gain over course of life
- High energy diet
• Had increased weight gain over the course of life in comparison to CHOW
- HE mice were then placed on CHOW
- Mice lost weight
- These mice were then allowed to consume food at will
- These mice ate amounts such that they regained the weight lost and rebounded to their previous weight
Conclusion:
• Greater body mass is ‘defended’
(What is the driver to this?
Hormones)
Describe the VLCD
Very low calorie diet
- Energy intake limited to 1.88-3.35 MJ daily
- > 50g protein
- Essential fatty acids
- Trace elements, vitamins, minerals
- Fibre (to lessen hunger & constipation)
- Lasts 8-16 weeks
Only recommended in BMI > 30 (or 27 if there are one or more co-morbidities)
Describe the efficacy of diets in achieving and sustaining weight loss
Diets invariably fail
Weight may be lost initially, but the weight is then regained
This is the same whether it be VLCD alone, or in conjunction with exercise and/or behavioural therapy
Describe Proietto’s 2011 paper that investigated long term persistence of hormonal adaptations to weight loss
Was looking at why diets fail to sustain weight loss
- Group of overweight individuals in study
- Baseline post-prandial hormone levels were measured (Ghrelin, PYY, CCK, Amylin)
- Intervention: VLCD
- Post-prandial hormone levels were re-tested
Results; after weight loss: • Increased Ghrelin post-prandially • Decreased CCK • Decreased amylin • Decreased PYY • Decreased leptin • Increased 'Hunger' • Increased 'Desire to eat'
- Weight was regained after intervention
- Post-prandial hormone levels were retested
• Hunger suppressive hormones were still lower, and Ghrelin levels were still elevated
Implication:
• When weight is lost, the body alters hormone levels that have the net effect of increasing hunger
• These hormonal changes persist even after weight is regained
Describe the changes in energy expenditure when weight is lost or gained
Weigh gained:
• Increased energy expenditure
Weight lost:
• Decreased energy expenditure
This decreased energy expenditure persists for a long time after the weight is lost
Describe pharmacotherapy for weight loss
- Phentermine
- Topiramate (off-label)
- Combination of the two
Diabetes:
- Exenatide
- Liraglutide
What are off-label drugs?
Use of the drug when it has not been approved for that use
Describe the effects of the drug Topiramate
Results in sustained weight loss after VLCD intervention, in comparison to placebo
However, has nasty adverse effects
Describe the efficacy of Ph/T combination therapy
Lead to more profound weigh loss than Phentermine on its own
Describe the side effects of Phentermine and Topiramate
Phentermine: • Increased HR and BP • Dry mouth • Sleep disturbances • Interactions with SSRIs
Topiramate: • Parasthesiae • Depression • Memory loss • etc.
Describe Proietto’s recent paper looking at Ph/T combination therapy for weight loss
103 patients
The majority did not complete the trial due to the adverse effects
Those that remained on the drug had sustained weight loss
Describe the various options for bariatric surgery, and how each works
- Adjustable gastric banding
• Band placed around the cardia of the stomach
• Size of stomach greatly restricted - Sleeve gastrectomy
• Large portion of stomach removed
• Lose cells that produce Ghrelin (-> reduced hunger) - Roux-en-Y bypass
• Bypass from cardia of stomach directly to intestine
• Undigested food in the small intestine stimulates the release of hunger suppressing hormones
Describe how the individual components of MS can be managed
- Diabetes
a. Pharmacological
• Metformin
• Insulin therapy
• GLP-1 enhancing drugs
• Acarbose
• Sulphonylureas
b. Non-pharmacological
• Diet
• Exercise - BP
a. Pharmacological
• Beta blockers
• ACE inhibitors
• Thiazide diuretics
• Angiotensin II receptor blockers
• Ca2+ channel blockers
b. Non-pharmacological:
• Reduced salt intake
- Lipids
a. Pharmacological
• TAGs: Fenofibrinate
• LDL: Statins
b. Non-pharmacological:
• Diet
• Exercise - Hyperuricaemia
• Allopurinol